Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29339717 | 0.73 | RAB9A (0.37) | ALDH1A1LMNANPC1MAPTRAB9A | |
| SCHEMBL24014929 | 0.73 | SMN1; SMN2 (0.43) | ALDH1A1LMNANPC1MAPTRAB9A | |
| SCHEMBL17196353 | 0.72 | KDR (0.33) | — | |
| SCHEMBL22979883 | 0.72 | NOTUM (0.38) | ALDH1A1LMNANPC1MAPTRAB9A | |
| SCHEMBL25784307 | 0.72 | ELANE (0.39) | ALDH1A1LMNANPC1MAPTRAB9A | |
| SCHEMBL25237034 | 0.71 | LRRK2 (0.34) | DRD2DRD4DRD3 | |
| SCHEMBL22979405 | 0.69 | KDM4E (0.36) | ALDH1A1LMNANPC1MAPT | |
| SCHEMBL22979644 | 0.68 | TSHR (0.40) | ALDH1A1LMNAMAPT | |
| SCHEMBL29340101 | 0.68 | NPC1 (0.31) | ALDH1A1LMNANPC1MAPTRAB9A | |
| SCHEMBL1359607 | 0.68 | LRRK2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725544-B1 | 3-[4-HETEROCYCLYL-1,2,3-TRIAZOL-1-YL]-N-ARYL-BENZAMIDES AS INHIBITORS OF THE CYTOKINES PRODUCTION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-05-27 | — | — | EP | disclosed |